查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1908174

抗高血壓藥物市場規模、佔有率和趨勢分析報告：按產品類型、劑型、給藥途徑、分銷管道、地區和細分市場預測（2026-2033 年）

Anti-hypertensive Drugs Market Size, Share & Trends Analysis Report By Product (ACE Inhibitors, Angiotensin II Receptor Blockers ), By Type, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

抗高血壓藥物市場概覽

2025年全球抗高血壓藥物市場規模估計為258.8億美元，預計2033年將達353.2億美元。

預計從 2026 年到 2033 年，該市場將以 3.96% 的複合年成長率成長。推動該市場成長的因素包括人口老化、久坐的生活方式、肥胖和都市化導致高血壓患者數量增加。

人們對心血管健康的日益重視、藥物研發的進步、新型固定劑量組合藥物的推出以及診斷技術的改進正在推動市場需求。新興國家醫療基礎設施的擴張也促進了市場成長。高血壓會增加心臟病和中風的風險，而心臟病和中風是美國的主要死因。根據美國疾病管制與預防中心 (CDC) 2025 年 1 月發布的數據，高血壓影響著近一半的美國成年人，每年導致超過 66.4 萬人死亡，並造成 1,310 億美元的經濟損失。男性盛行率 (50%) 高於女性 (44%)，黑人成年人盛行率最高 (58%)，其次是白人 (49%)、亞裔 (45%) 和西班牙裔 (39%)。只有四分之一的高血壓患者血壓得到控制，而且不同性別、種族和地區之間有顯著差異。數百萬高血壓患者仍未接受治療，尤其是重度高血壓患者。高血壓控制不佳的高發生率和較低的治療依從性導致降血壓藥物需求強勁。高血壓為醫療保健系統帶來的日益成長的成本，促使人們進一步投資於有效的治療方法，並推動全球降血壓藥物產業的擴張。

近期監管部門的核准和積極的臨床試驗結果正在推動市場成長並重塑治療策略。例如，2025年6月，喬治醫藥公司（George Medicines）的WIDAPLIK獲得FDA核准，這是第一個用於治療成人高血壓（包括一線治療）的單片聯合治療（Telmisartan、氨氯地平和吲達帕胺）。 WIDAPLIK提供三種劑量規格，滿足了高血壓管理中常見的多種藥物聯合用藥的需求，並以簡化的形式展現了聯合治療的優勢。該藥預計將於2025年第四季在美國商業性，並計劃提交其他全球監管申請。 WIDAPLIK的核准代表著抗高血壓行業的一項重大創新，為新確診和血壓控制不佳的患者帶來了一種便捷的、First-in-Class的聯合治療。簡化治療方案和提高用藥依從性預計將推動美國市場的強勁需求，因為美國約有一半的成年人患有高血壓，但只有四分之一的患者能夠有效控制血壓。這項核准有望推動單片療法的普及，並為全球高血壓管理樹立新的標準。

此外，2024年4月，Alnylam Pharmaceuticals公司宣布了其在研RNAi療法dilbesiran的II期KARDIA-2研究的正面結果。此療法針對血管張力素原（AGT），用於治療難治性高血壓。研究發現，在標準降血壓藥物（吲達帕胺、氨氯地平或Olmesartan）的基礎上，單次皮下注射600毫克dilbesiran，三個月後可顯著降低患者的活動性收縮壓（ACTBP），降幅高達12.1 mmHg，且療效永續六個月。 Dilbesiran是第一個用於治療高血壓的RNAi療法，其長效給藥方案（每年兩次）有望為傳統口服降血壓藥市場增添新的選擇。透過提高患者的用藥依從性並實現持續的血壓控制，Dilbesiran滿足了難治性高血壓患者的重要未滿足醫療需求。這種藥物的成功可能將精準醫療和生技藥品療法擴展到傳統治療方法之外，從而徹底改變抗高血壓藥物產業。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 抗高血壓藥物市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析

第4章 抗高血壓藥物市場：依產品分類的業務分析

  • 按產品分類的市場佔有率（2025 年和 2033 年）
  • 按產品分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 血管緊張素轉換酶抑制劑（ACEI）
  • 血管收縮素II受體阻斷劑（ARB）
  • 直接腎素抑制劑
  • 鈣離子通道阻斷劑
  • 利尿劑
  • 鹽皮質激素受體拮抗劑（MRA）
  • BETA阻斷劑
  • α1阻斷劑
  • 中樞α2促效劑
  • 直接血管擴張劑
  • 固定劑量組合藥物（FDC）
  • 其他

第5章 抗高血壓藥物市場：按類型分類的業務分析

  • 按類型分類的市場佔有率（2025 年和 2033 年）
  • 按類型分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 正常高血壓
  • 難治性高血壓
  • 高血壓急症/緊急狀況

第6章：抗高血壓藥物市場：依給藥途徑進行業務分析

  • 按給藥途徑分類的市場佔有率（2025 年和 2033 年）
  • 按給藥途徑分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 口服
  • 經皮
  • 腸外/靜脈注射

第7章：抗高血壓藥物市場：按分銷管道分類的業務分析

  • 按分銷管道分類的市場佔有率（2025 年和 2033 年）
  • 按分銷管道分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 零售藥房
  • 醫院藥房
  • 其他

第8章：抗高血壓藥物市場：各國估算與趨勢分析

  • 各國市場（2025 年和 2033 年）
  • 各國市場概覽
  • 市場規模及預測趨勢分析，2021-2033年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭情勢

  • 參與公司概況
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/列表
    • Novartis
    • Sanofi
    • Bayer
    • Boehringer Ingelheim International GmbH
    • DAIICHI SANKYO COMPANY, LIMITED
    • Takeda Pharmaceutical Company Limited
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz（Novartis）
    • Sun Pharmaceutical Industries Ltd.
Product Code: GVR-4-68040-166-1

Anti-hypertensive Drugs Market Summary

The global anti-hypertensive drugs market size was estimated at USD 25.88 billion in 2025 and is projected to reach USD 35.32 billion by 2033, growing at a CAGR of 3.96% from 2026 to 2033. The market is driven by the rising prevalence of hypertension due to aging populations, sedentary lifestyles, obesity, and urbanization.

Increasing awareness of cardiovascular health, advances in drug development, introduction of novel fixed-dose combinations, and improved diagnostics are boosting demand. Expanding healthcare infrastructure in emerging economies further supports market expansion. High blood pressure (hypertension) increases the risk of heart disease and stroke, two major causes of death in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC) in January 2025, high blood pressure affects nearly half of U.S. adults, causes over 664,000 deaths annually, and costs USD 131 billion each year. Prevalence is higher in men (50%) vs. women (44%), and highest among Black adults (58%), followed by Whites (49%), Asians (45%), and Hispanics (39%). Only 1 in 4 people with hypertension have it under control, with disparities across sex, race, and geography. Millions remain untreated, especially those with severely elevated blood pressure. The high prevalence of uncontrolled hypertension and low treatment adherence has driven strong demand for antihypertensive drugs. Rising costs of hypertension to the healthcare system further support investment in effective therapies, expanding the global anti-hypertensive drugs industry.

Recent regulatory approvals and positive clinical trial outcomes have accelerated market growth and reshaped therapeutic strategies. For instance, in June 2025, George Medicines received FDA approval for WIDAPLIK, the first and only single-pill triple combination therapy (telmisartan, amlodipine, indapamide) for hypertension in adults, including as an initial treatment. Available in three dosage strengths, WIDAPLIK offers the benefits of combination therapy in a simplified form, addressing the common need for multiple medications in hypertension management. The U.S. commercial launch is expected in Q4 2025, with additional global regulatory submissions planned. The approval of WIDAPLIK marks a significant innovation in the anti-hypertensive drugs industry, introducing a convenient, first-in-class triple combination therapy for newly diagnosed and uncontrolled patients. By simplifying treatment and improving adherence, it is expected to capture strong demand in the US, where nearly half of adults have hypertension but only one in four has it under control. This approval strengthens the shift towards single-pill combinations and is likely to set new benchmarks for hypertension management globally.

Furthermore, in April 2024, Alnylam Pharmaceuticals announced positive results from the Phase 2 KARDIA-2 trial, evaluating zilebesiran, an investigational RNAi-based therapy targeting angiotensinogen (AGT) for uncontrolled hypertension. A single 600 mg subcutaneous dose added to standard antihypertensives (indapamide, amlodipine, or olmesartan) achieved significant reductions in ambulatory systolic BP of up to 12.1 mmHg at 3 months and sustained reductions up to 6 months. Zilebesiran represents a first-in-class RNAi therapeutic in hypertension, offering a long-acting, twice-yearly dosing option that could disrupt the traditional oral drug market. By improving adherence and providing consistent BP control, it targets a major unmet need in patients with uncontrolled hypertension. Its success could significantly reshape the anti-hypertensive drugs industry, expanding precision and biologics-based approaches beyond conventional therapies.

Global Anti-hypertensive Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global anti-hypertensive drugs market report based on product, type, route of administration, distribution channel, and region.

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • ACE Inhibitors (ACEIs)
  • Angiotensin II Receptor Blockers (ARBs)
  • Direct Renin Inhibitor
  • Calcium Channel Blockers
  • Diuretics
  • Mineralocorticoid Receptor Antagonists (MRAs)
  • Beta-blockers
  • Alpha-1 Blockers
  • Central Alpha-2 Agonists
  • Direct Vasodilators
  • Fixed-dose Combinations (FDCs)
  • Others
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Standard Hypertension
  • Treatment-resistant Hypertension
  • Hypertensive Emergency/ Urgency
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Oral
  • Transdermal
  • Parenteral / Intravenous
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Retail Pharmacy
  • Hospital Pharmacy
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Anti-hypertensive Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Anti-hypertensive Drugs Market: Product Business Analysis

  • 4.1. Product Market Share, 2025 & 2033
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. ACE Inhibitors (ACEIs)
    • 4.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Angiotensin II Receptor Blockers (ARBs)
    • 4.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Direct Renin Inhibitor
    • 4.6.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Calcium Channel Blockers
    • 4.7.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Diuretics
    • 4.8.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.9. Mineralocorticoid Receptor Antagonists (MRAs)
    • 4.9.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.10. Beta-Blockers
    • 4.10.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.11. Alpha-1 Blockers
    • 4.11.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.12. Central Alpha-2 Agonists
    • 4.12.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.13. Direct Vasodilators
    • 4.13.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.14. Fixed-Dose Combinations (FDCs)
    • 4.14.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.15. Others
    • 4.15.1. Market Size & Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Anti-hypertensive Drugs Market: Type Business Analysis

  • 5.1. Type Market Share, 2025 & 2033
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 5.4. Standard Hypertension
    • 5.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Treatment-Resistant Hypertension
    • 5.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Hypertensive Emergency/Urgency
    • 5.6.1. Market Size & Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Anti-hypertensive Drugs Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2025 & 2033
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
  • 6.4. Oral
    • 6.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Transdermal
    • 6.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Parenteral / Intravenous
    • 6.6.1. Market Size & Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Anti-hypertensive Drugs Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2025 & 2033
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 7.4. Retail Pharmacy
    • 7.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Hospital Pharmacy
    • 7.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Other
    • 7.6.1. Market Size & Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Anti-hypertensive Drugs Market: Countries Estimates & Trend Analysis

  • 8.1. Country Market Share Analysis, 2025 & 2033
  • 8.2. Country Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
    • 8.3.1. U.S.
      • 8.3.1.1. Key Country Dynamics
      • 8.3.1.2. Target Disease Prevalence
      • 8.3.1.3. Regulatory Framework
      • 8.3.1.4. Reimbursement Framework
      • 8.3.1.5. Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Target Disease Prevalence
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. Reimbursement Framework
      • 8.3.2.5. U.S. Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Reimbursement Framework
      • 8.3.3.5. Mexico Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4. Europe
    • 8.4.1. Europe Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.2. UK
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. UK Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Germany
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. Germany Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. France
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. France Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.5. Italy
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Reimbursement Framework
      • 8.4.5.5. Italy Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.6. Spain
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Reimbursement Framework
      • 8.4.6.5. Spain Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.7. Denmark
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Reimbursement Framework
      • 8.4.7.5. Denmark Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.8. Sweden
      • 8.4.8.1. Key Country Dynamics
      • 8.4.8.2. Target Disease Prevalence
      • 8.4.8.3. Regulatory Framework
      • 8.4.8.4. Reimbursement Framework
      • 8.4.8.5. Sweden Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.9. Norway
      • 8.4.9.1. Key Country Dynamics
      • 8.4.9.2. Target Disease Prevalence
      • 8.4.9.3. Regulatory Framework
      • 8.4.9.4. Reimbursement Framework
      • 8.4.9.5. Norway Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Asia Pacific Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. Japan
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. Japan Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. China
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. China Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. India
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. India Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Australia
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Australia Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. South Korea
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. South Korea Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. Thailand
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Thailand Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Latin America Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Brazil
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. Argentina
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Middle East and Africa
    • 8.7.1. Middle East and Africa Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. South Africa
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. South Africa Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Saudi Arabia
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. Saudi Arabia Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.4. UAE
      • 8.7.4.1. Key Country Dynamics
      • 8.7.4.2. Target Disease Prevalence
      • 8.7.4.3. Regulatory Framework
      • 8.7.4.4. Reimbursement Framework
      • 8.7.4.5. UAE Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.5. Kuwait
      • 8.7.5.1. Key Country Dynamics
      • 8.7.5.2. Target Disease Prevalence
      • 8.7.5.3. Regulatory Framework
      • 8.7.5.4. Reimbursement Framework
      • 8.7.5.5. Kuwait Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Novartis
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Sanofi
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Bayer
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Boehringer Ingelheim International GmbH
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. DAIICHI SANKYO COMPANY, LIMITED
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Takeda Pharmaceutical Company Limited
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Viatris Inc.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Teva Pharmaceutical Industries Ltd.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Sandoz (Novartis)
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Sun Pharmaceutical Industries Ltd.
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global Anti-hypertensive Drugs Market, by Region, 2021 - 2033 (USD Million)
  • Table 3 Global Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 4 Global Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 5 Global Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 6 Global Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 7 North America Anti-hypertensive Drugs Market, by Country, 2021 - 2033 (USD Million)
  • Table 8 North America Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 9 North America Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 10 North America Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 11 North America Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 12 U.S. Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 13 U.S. Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 14 U.S. Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 15 U.S. Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 16 Canada Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 17 Canada Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 18 Canada Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 19 Canada Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 20 Mexico Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 21 Mexico Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 22 Mexico Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 23 Mexico Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 24 Europe Anti-hypertensive Drugs Market, by Country, 2021 - 2033 (USD Million)
  • Table 25 Europe Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 26 Europe Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 27 Europe Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 28 Europe Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 29 Germany Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 30 Germany Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 31 Germany Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 32 Germany Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 33 UK Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 34 UK Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 35 UK Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 36 UK Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 37 France Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 38 France Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 39 France Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 40 France Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 41 Italy Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 42 Italy Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 43 Italy Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 44 Italy Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 45 Spain Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 46 Spain Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 47 Spain Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 48 Spain Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 49 Denmark Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 50 Denmark Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 51 Denmark Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 52 Denmark Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 53 Sweden Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 54 Sweden Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 55 Sweden Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 56 Sweden Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 57 Norway Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 58 Norway Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 59 Norway Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 60 Norway Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 61 Asia Pacific Anti-hypertensive Drugs Market, by Country, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 66 China Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 67 China Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 68 China Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 69 China Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 70 Japan Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 71 Japan Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 72 Japan Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 73 Japan Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 74 India Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 75 India Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 76 India Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 77 India Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 78 South Korea Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 79 South Korea Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 80 South Korea Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 81 South Korea Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 82 Australia Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 83 Australia Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 84 Australia Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 85 Australia Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 86 Thailand Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 87 Thailand Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 88 Thailand Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 89 Thailand Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 90 Latin America Anti-hypertensive Drugs Market, by Country, 2021 - 2033 (USD Million)
  • Table 91 Latin America Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 92 Latin America Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 93 Latin America Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 94 Latin America Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 95 Brazil Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 96 Brazil Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 97 Brazil Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 98 Brazil Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 99 Argentina Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 100 Argentina Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 101 Argentina Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 102 Argentina Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 103 Middle East & Africa Anti-hypertensive Drugs Market, by Country, 2021 - 2033 (USD Million)
  • Table 104 Middle East & Africa Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 105 Middle East & Africa Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 106 Middle East & Africa Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 107 Middle East & Africa Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 108 South Africa Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 109 South Africa Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 110 South Africa Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 111 South Africa Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 112 Saudi Arabia Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 116 UAE Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 117 UAE Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 118 UAE Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 119 UAE Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 120 Kuwait Anti-hypertensive Drugs Market, by Product , 2021 - 2033 (USD Million)
  • Table 121 Kuwait Anti-hypertensive Drugs Market, by Type, 2021 - 2033 (USD Million)
  • Table 122 Kuwait Anti-hypertensive Drugs Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 123 Kuwait Anti-hypertensive Drugs Market, by Distribution Channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Anti-hypertensive Drugs Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product Segment snapshot
  • Fig. 10 Type and Route of Administration Segment Snapshot
  • Fig. 11 Distribution channel segment snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Parent market (USD Billion)
  • Fig. 14 Market dynamics
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 PESTLE Analysis
  • Fig. 17 Anti-hypertensive Drugs market: Indication outlook and key takeaways
  • Fig. 18 Anti-hypertensive drugs market: product movement analysis
  • Fig. 19 ACE Inhibitors (ACEIs) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 20 Angiotensin II Receptor Blockers (ARBs) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 21 Direct Renin Inhibitor market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Calcium Channel Blockers (CCBs) [Dihydropyridines, Non Dihydropyridines] market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Diuretics (non-MRA) [Thiazide & Thiazide-like, Loop Diuretics, Potassium-Sparing (non-MRA)] market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 Mineralocorticoid Receptor Antagonists (MRAs) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Beta-Blockers [Cardioselective, Non-selective / Mixed] market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Alpha-1 Blockers market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Central Alpha-2 Agonists market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 Direct Vasodilators market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Fixed-Dose Combinations (FDCs) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 30 Other market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 31 Anti-hypertensive Drugs market: Type outlook and key takeaways
  • Fig. 32 Anti-hypertensive Drugs market: Type movement analysis
  • Fig. 33 Standard Hypertension (patients controlled with <=3 agents) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 34 Treatment-Resistant Hypertension (TRH) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 35 Hypertensive Emergency/Urgency (IV/acute use) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 36 Anti-hypertensive drugs market: Route of administration outlook and key takeaways
  • Fig. 37 Anti-hypertensive drugs market: Route of administration movement analysis
  • Fig. 38 Oral (tablets, capsules) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 39 Transdermal (patches) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 40 Parenteral / Intravenous market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 41 Anti-hypertensive drugs market: Distribution channel outlook and key takeaways
  • Fig. 42 Anti-hypertensive drugs market: Distribution channel movement analysis
  • Fig. 43 Hospital pharmacy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 44 Retail pharmacy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 45 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Anti-hypertensive Drugs market revenue, by region, 2021 & 2033 (USD Million)
  • Fig. 47 Regional marketplace: Key takeaways
  • Fig. 48 Regional marketplace: Key takeaways
  • Fig. 49 North America anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 U.S. anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 General reimbursement pattern in the U.S.
  • Fig. 53 Key country dynamics
  • Fig. 54 Canada anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Mexico anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Regulatory framework
  • Fig. 58 Europe anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 UK anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Germany anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 France anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Spain anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Italy anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Denmark anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 Sweden anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Norway anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Rest of Europe anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Asia Pacific anti-hypertensive drugs market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Japan anti-hypertensive drugs market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 China anti-hypertensive drugs market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 81 China regulatory details
  • Fig. 82 Key country dynamics
  • Fig. 83 India anti-hypertensive drugs market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Australia anti-hypertensive drugs market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Thailand anti-hypertensive drugs market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 South Korea anti-hypertensive drugs market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 90 South Korea reimbursement scenario
  • Fig. 91 Rest of Asia Pacific anti-hypertensive drugs market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 92 Latin America anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 Brazil anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 95 Brazil regulation details
  • Fig. 96 Brazil reimbursement scenario
  • Fig. 97 Key country dynamics
  • Fig. 98 Argentina anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 99 Argentina regulatory framework
  • Fig. 100 Rest of Latin America anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 101 MEA anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 102 Key country dynamics
  • Fig. 103 South Africa anti-hypertensive drugs market estimates and forecasts, 2021 - 2033, (USD Million)
  • Fig. 104 Key country dynamics
  • Fig. 105 Saudi Arabia anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 106 Key country dynamics
  • Fig. 107 UAE anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 108 Key country dynamics
  • Fig. 109 Kuwait anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 110 Rest of MEA anti-hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)